Table 1.
Role of WNT components in drug resistance.
| WNT component | Role in drug resistance | Type of cancer | References |
|---|---|---|---|
| FZD1 increase | Increased ABCB1 expression | Solid and hematological tumors Human myelogenous leukemia |
(95, 96) |
| FZD1 increase | Increased ABCB1 expression and efflux activity | Neuroblastoma | (97, 98) |
| FZD7 increase | Increased ABCB1 expression | Hepatocellular carcinoma | (99) |
| SFRPs methylation | Increased ABCB1 expression | Several types of leukemia Ovarian cancer Cervical cancer Breast cancer |
(100) |
| LGR5 increase | Increased ABCB1 expression | Colorectal cancer | (101) |
| YAP/TAZ increase | Increased drug resistance | Breast cancer Melanoma |
(102, 103) |
| PYGO2 overexpression | Increased ABCB1 expression | Breast cancer | (104) |
| APC mutations | Increased CD44v6 expression | Colorectal cancer | (105) |
| CK1a and GSK3a/b inactivation | Increased drug resistance | Multiple myeloma | (106, 107) |
| Undefined WNT mediators | Increased CD44 expression | Multiple myeloma | (108) |